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Abstract
Opioid use disorder during pregnancy has continued to rise, and more primary care
providers are being encouraged to prescribe opioid agonist pharmacotherapy. Such medications
include methadone, buprenorphine, and naloxone. Many studies have been done to compare
these medications’ role in medication assisted treatment (MAT) in pregnant women with opioid
use disorder.
The purpose of this literature review is to compare the use e of buprenorphine, with and
without naloxone, as MAT for opioid dependent pregnant women. Specific outcomes compared
in this study include maternal and neonatal safety, neonatal abstinence syndrome, and peripartum
pain management. This review included three electronic search databases: PubMed, Clinical
Key, and Cochrane library from September 1, 2019 to March 1, 2020. The search included
randomized control trials, systematic reviews, and meta-analysis that were published in the last
25 years.
Several of the presented studies show evidence to support of buprenorphine monotherapy
and buprenorphine-naloxone combination therapy. Majority of the research suggest overall
insufficient evidence to declare one therapy superiority compared to the other. Many studies
discuss the complications and limitations with regards to medication trials in pregnant and opioid
dependent populations. Ultimately, more research and clinical trials are needed in order to claim
the safety and efficacy in the use of buprenorphine as MAT in pregnant women with opioid
dependence.
Key terms: buprenorphine in pregnancy, buprenorphine-naloxone in pregnancy, naloxone
in pregnancy, buprenorphine safety, suboxone, Subutex, buprenorphine and neonatal abstinence
syndrome, pain management buprenorphine, peripartum pain management buprenorphine.
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Introduction
In recent studies by the Center for Disease Control (2019), opioid use disorder during
pregnancy has continued to rise. From 1999 to 2014 the number of women with opioid use
disorder at the time of delivery has quadrupled. Opioid agonist pharmacotherapy, also referred to
as medication assisted treatment (MAT) first began in the 1970s for pregnant women with heroin
addiction. Since then, such medications have been used in pregnant women with opioid use
disorder. The two primary medications of MAT include Methadone and Buprenorphine. The
goal of MAT during pregnancy is to prevent maternal opioid withdrawal, prevent relapse, reduce
neonatal opioid exposure, and improve fetal outcomes. One main concern of opioid use and
MAT is neonatal abstinence syndrome (NAS). Neonatal abstinence syndrome is a range of
symptoms that may result from chronic maternal opioid use during pregnancy and can occur in
30-80% of MAT mothers.
The purpose of this literature review is to further understand the role of buprenorphine,
with and without naloxone, as MAT for opioid dependent pregnant women. Furthermore, the
specific outcomes compared include maternal and neonatal safety, neonatal abstinence
syndrome, and peripartum pain management. This knowledge will help providers to make an
educated an appropriate choice when choosing MAT therapy for pregnant mothers with opioid
dependence.
Statement of the Problem
According to the Substance Abuse and Mental Health Services Administration
(SAMHSA), in 2013 there were an estimated 1.8 million people with opioid use disorder related
to prescription medications and 517,000 related to heroin. SAMHSA reports there are currently
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less than 100,000 providers nationwide that have undergone the buprenorphine wavier program
under the Drug Addiction Treatment Act of 2000 (DATA). It is clear to see there is not a enough
providers certified for MAT when looking at the number of individuals suffering with opioid use
disorder. Thus, as an increasing number of providers are advised to undergo MAT training and
certification. Furthermore, these providers should be informed on the use of such medication in
pregnant women to make the safest and most effective choice. The FDA has approved two
medications for use of opioid dependent pregnant women, methadone and buprenorphine.
Furthermore, buprenorphine can be used as monotherapy, or combination therapy of
buprenorphine and naloxone. Previous research has compared the use of methadone to
buprenorphine. This literature review will compare buprenorphine monotherapy to
buprenorphine-naloxone combination therapy in opioid dependent pregnant women. Specific
outcomes in this comparison include maternal adherence, neonatal abstinence syndrome, and
peripartum pain management to aid in determining the treatment option with greatest benefits
and least risk for mother and baby.
Research Questions
In opioid dependent pregnant women, how does use of buprenorphine-naloxone compare
to buprenorphine monotherapy in maternal and neonatal safety?
In opioid dependent pregnant women, how does use of buprenorphine-naloxone compare
to buprenorphine monotherapy in reduction of NAS?
In opioid dependent pregnant women, how does use of buprenorphine-naloxone
compared to buprenorphine monotherapy effect management of peripartum pain?
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Methodology
A literature review was performed using electronic search databases: PubMed, Clinical
Key, and Cochrane library. Keyword and mesh terms included: buprenorphine in pregnancy,
buprenorphine-naloxone in pregnancy, naloxone in pregnancy, buprenorphine safety, suboxone,
Subutex, buprenorphine and neonatal abstinence syndrome, pain management buprenorphine,
peripartum pain management buprenorphine. Many articles used the same research studies and
were not original studies, so some were excluded. Several studies compared buprenorphine to
methadone, looking at similar outcomes, many of these studies were also excluded. PubMed
served as the primary database for this literature review. Several studies were excluded as they
did not solely look at use of buprenorphine as MAT or its use in pregnant women. The data
search time frame included studies completed in the last ten years.
Review of Literature
A review of the literature has been conducted which shows that there is evidence to
support use of methadone or buprenorphine in pregnant women with opioid dependence.
Furthermore, buprenorphine can be used with or without naloxone. There are many concerns
about the use of naloxone in pregnancy as it is an opioid antagonist, however buprenorphine
monotherapy has higher potential for misuse (ACOG, 2017). The goal of selecting the best
medication for opioid dependent mothers includes several factors including maternal adherence
and risk of withdrawal, obstetric complications, impaired fetal development, and neonatal
abstinence syndrome. Limitations to the study include small sample size, maternal adherence,
natural variants in maternal and neonatal pregnancy outcomes, duration and dosing of MAT.
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Maternal and neonatal safety outcomes with buprenorphine monotherapy versus
buprenorphine-naloxone combination therapy.
A 2018 article in American Family Physician by Zoorob et al., discusses use of
buprenorphine in opioid use disorder. Buprenorphine is a schedule III medication and is
manufactured in two formulations, buprenorphine monotherapy and combination buprenorphinenaloxone. Combination therapy is preferable over monotherapy in most patients due to its lower
risk of misuse. However, monotherapy is preferred in pregnant and lactating women because
neonatal exposure to naloxone is not very well studied and misuse, such as injecting, naloxone
containing product can induce opioid withdrawal. Both monotherapy and combination therapy
are well tolerated with the most common side effects including anxiety, constipation, dizziness,
drowsiness, headache, nausea, and sedation. More serious adverse effects include accidental
ingestion and overdose, hepatitis and hepatic events, opioid withdrawal effects particularly in
combination products, perinatal effects, or respiratory depression in patients with compromised
respiratory function. This article serves to provide baseline knowledge and understanding of the
medication, use, and potential side effects.
An article from 2003 in Drug and Alcohol Dependence Journal by Johnson et al., outlines
information for providers regarding information about the formulations, use, and side effects of
both buprenorphine-monotherapy and buprenorphine-naloxone. Buprenorphine is a mu-receptor
agonist, with high affinity, low intrinsic activity, and slow dissociation. These qualities allow
buprenorphine to have a good safety profile, low physical dependence, and flexibility in dose
scheduling. Furthermore, buprenorphine has been formulated into a combination sublingual
tablet with naloxone in a 4:1 ratio. Naloxone is an opioid antagonist, however, has poor
sublingual absorption, therefore provides minimal opioid antagonist effects. The combination
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product of buprenorphine-naloxone was developed to decrease the risk of diversion and abuse of
buprenorphine monotherapy, in the event the medication is used parenterally, naloxone will
cause the predominant effect resulting in withdrawal. The 2003 article by Johnson et al. reports
that buprenorphine-naloxone has been tested in over 5,000 opioid-dependent individuals in the
U.S., and no apparent side effects have been reported. Similar to that of opioids however,
buprenorphine can cause constipation. Additionally, there have been some reports of individuals
whom experience elevated liver enzymes. Liver toxicity has been associated with intravenous
buprenorphine misuse, due to the increased bioavailability when administered parenterally.
In 2016, Jumah et al. preformed an observational, retrospective study of 855 pregnant
women, including 62 women expose to buprenorphine-naloxone, 618 women with no opioid
exposure, and 159 women with opioid exposure other than buprenorphine-naloxone. The
outcomes assessed included birth weight, preterm delivery, congenital anomalies, still birth,
Apgar score at 1 and 5 minutes, NAS score >7, and treatment of NAS. Maternal outcomes
included cesarean sections, postpartum hemorrhages, and out of hospital deliveries and transfer
of care. Results showed no difference between Apgar scores and caesarean section rates between
buprenorphine-naloxone exposure and no opioid exposure. Additionally, mothers using
buprenorphine-naloxone had higher birth-weight babies compared to mothers taking other
opioids (p=0.001). This study suggests that buprenorphine-naloxone use by opioid dependent
mothers during pregnancy causes no significant harm. This study is beneficial in understanding
the benefits versus risks of buprenorphine use during pregnancy for both mother and baby, and
additionally includes use of naloxone. Overall, no significant complications or safety concerns
were identified. This study strongly supports use of buprenorphine-naloxone in pregnancy
(Jumah et al., 2016).
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Lund et al. performed a comparison review in 2013 of previously published studies on
buprenorphine pharmacotherapy during pregnancy. A comparison study was done to evaluate
maternal and neonatal outcomes with use of buprenorphine-naloxone compared to buprenorphine
monotherapy in treatment of opioid dependent mothers. Maternal outcomes reported included
cesarean sections, days of maternal hospital stay, maternal weight gain, non-normal delivery
presentation, analgesia during delivery, drug-screen at delivery, medication complications at
deliver, number of prenatal obstetrical visits, fetal presentation at delivery, and breast feeding.
Despite limitations including small sample size and retrospective study, there were no obvious
adverse maternal or neonatal outcomes related to the use of buprenorphine-naloxone
combination therapy in the treatment of opioid-dependent mothers. The maternal outcomes
assessed were similar to those previously identified in women using buprenorphine
monotherapy. This study is beneficial as it evaluates maternal and neonatal safety with use of
buprenorphine-naloxone and concludes there were no significant differences compared to use of
buprenorphine monotherapy in the pregnant population (Lund et al., 2013).
Poon et al. conducted a study in 2014 with the goal of comparing the safety of newer
opioid antagonists used in pregnancy, including buprenorphine and buprenorphine-naloxone.
The main concern with buprenorphine- naloxone is its potential for abuse used intravenously or
intranasally, in which case the naloxone causes severe withdrawal in opioid dependent patients.
Regarding maternal safety, a retrospective chart review of opioid dependent mothers treated with
buprenorphine-naloxone was done. The study included women who began treatment prior to
conceptions (n = 8) or within the first trimester (n= 2). Of these mothers, no significant adverse
maternal or neonatal outcomes were reported compared to the mothers receiving buprenorphine
monotherapy. Although sample size is small, it was concluded that both buprenorphine
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monotherapy and combination therapy are safe and effective treatment options for opioid
dependent mothers. Furthermore, they recommend women who become pregnant while taking
buprenorphine-naloxone treatment are advised to transition to buprenorphine monotherapy, as
there is greater risk of withdrawal caused by improper use of combination therapy. Despite small
sample size, this study is beneficial as it compares safety outcomes and includes
recommendations. There are many contradictory recommendations regarding whether it is safe
or appropriate to switch from one treatment to another after becoming pregnant. Additionally,
there are contradictory beliefs on whether buprenorphine-monotherapy or buprenorphinenaloxone have greater all-around risk if there is potential for abuse. Monotherapy abuse can
cause increased fetal opioid exposure, while combination therapy abuse can result in withdrawal.
Tran et al. conducted a review in 2017 to compare pregnancy outcomes with use of
methadone, buprenorphine, and naltrexone in clinical trials. Between methadone and
buprenorphine, buprenorphine is the preferred agent due to is shorter treatment duration, less
pharmacotherapy needed in treatment of NAS symptoms, and shorter hospitalizations needed for
neonates. Furthermore, buprenorphine monotherapy is preferable to buprenorphine-naloxone
during pregnancy due to avoidance of prenatal naloxone exposure. There is greater risk of
detoxification with use of naloxone during pregnancy. This study too shows skepticism of
including naloxone in pregnancy and uses naltrexone as a comparative treatment in MAT of
pregnant women. Additionally, this study expresses buprenorphine monotherapy as the
preferable treatment over buprenorphine-naloxone, as the previously discussed studies favored
combination therapy.
Neonatal abstinence syndrome with buprenorphine monotherapy versus buprenorphinenaloxone combination therapy.
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The objective of Debelak et al, in 2013 was to compare maternal and neonatal outcomes
following buprenorphine-naloxone exposure during pregnancy. A retrospective chart review
used 10 opioid-dependent pregnant women using buprenorphine-naloxone sublingual film.
Neonatal outcomes included measured-gestational age at delivery, 1- and 5-minute Apgar scores,
head circumference, length and weight at birth, treatment for NAS, total amount of morphine
sulfate needed for treatment of NAS, and length of hospital stay for treatment of NAS. Results
found neonates were full-term with normal birth parameters. Four of the ten neonates were
treated for NAS, and length of hospital stay for treatment of NAS were similar to that of
buprenorphine monotherapy. This study is valuable in that it suggests there are not only no
obvious significant maternal effects, but also no significant neonatal effects related to the use of
buprenorphine-naloxone in pregnant women. Limitations of this study include small sample size
(Debelak et al., 2013).
In the previously discussed study by Lund et al., comparing buprenorphine-naloxone and
buprenorphine monotherapy, neonatal outcomes were additionally observed. Neonates exposed
to buprenorphine-naloxone or buprenorphine monotherapy were born with comparable head
circumferences, both within normal range according to the World Health Organization (WHO).
The second significant neonatal outcome was Apgar scores at 5 minutes, in which the
buprenorphine-naloxone group was significantly lower than buprenorphine monotherapy group,
however both groups remained in the normal rage. Limitations of this study included small
sample size. This study is beneficial in revealing observed neonatal outcomes and concluding no
significant adverse effects with use of buprenorphine-monotherapy or buprenorphine-naloxone.
Although there were differences notes, neither group fell out of the normal ranges set by WHO.
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Mullins et al, performed a retrospective cohort study in 2019 of mothers with opioid use
disorder using buprenorphine monotherapy and buprenorphine-naloxone comparing maternal
and fetal outcomes. The primary fetal outcome assess was neonatal abstinence syndrome (NAS)
requiring treatment. Results found infants exposed to buprenorphine in utero experienced a
significantly higher rate of NAS 59/108 (54.6%), compared to infants exposed to buprenorphinenaloxone in utero experiencing NAS 30/85 (35.3%). In conclusion, when comparing
buprenorphine monotherapy to buprenorphine-naloxone, combination therapy had a lower rate of
NAS and can be considered an acceptable alternative treatment for opioid dependent pregnant
women. This retrospective study is very significant in comparing buprenorphine-monotherapy
against buprenorphine-naloxone and their effects on neonatal abstinence syndrome. Reducing
risk of NAS is one of the primary goals of MAT in pregnancy. The results of this study favor use
of buprenorphine-naloxone combination therapy for greater reduction of risk of NAS in neonates
born to mothers with opioid dependence receiving MAT (Mullins et al., 2019).
Another retrospective chart review performed by Nguyen et al. in 2018, includes 26
mothers in medication-assisted treatment programs using buprenorphine-naloxone during
pregnancy. The goal of this review was to examine the relationship of neonatal outcomes with
the use of buprenorphine-naloxone in pregnancy. Results demonstrated neonatal birth outcomes
all within normal ranges. Additionally, only 19% of the neonates includes required
pharmacological treatment for neonatal abstinence syndrome. This study concluded use of
buprenorphine- naloxone shows relative safety in pregnancy. This study also supports
buprenorphine-naloxone for its safety in pregnancy, improved neonatal birth outcomes, and
reduced requirement for treatment of NAS (Nguyen et al.,2018).
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Peripartum and postpartum pain management with buprenorphine monotherapy versus
buprenorphine-naloxone combination therapy.
In 2018, Hoyt et al. preformed an observational study to assess the standard labor
analgesia of fentanyl in bupivacaine epidural solution was substituted with clonidine in
bupivacaine. Pain scores were recorded during labor and immediately post-surgical. The study
included fourteen patients, seven presented in spontaneous labor and seven had elective cesarean
delivery. Of the women whom had spontaneous vaginal delivery, pain scores immediately postepidural ranged from 0/10-4/10. Of women having cesarean delivery, pain score after receiving
the epidural infusion pre-surgery was 0/10 for all patients and at time of epidural removal the
highest pain score was 5/10. This study revealed that clonidine and bupivacaine appear affective
in parturient on buprenorphine therapy for opioid addiction maintenance. Limitations of this
study include small sample size. Many challenges arise for providers when trying to manage pain
in patients receiving MAT as these patients have greater opioid tolerance and are receiving
opioid agonist and/or antagonists which can be difficult and dangerous. This study shows good
support for use of non-opioid medication for labor related pain management in patients receiving
buprenorphine (Hoyt et al., 2018).
A 2017 article by Pan et al. in the Journal of Clinical Obstetrics and Gynecology,
discusses peripartum, intrapartum, and post-partum anesthetic management and implications.
Pain management in individuals using buprenorphine products is a challenge. These patients may
experience altered baseline pain levels, requiring higher dosing to manage their pain. Mothers
should continue maintenance doses of buprenorphine produce; however this does not provide
labor analgesia. Pain management should be based on the clinical situation. Because
buprenorphine has high affinity for mu-receptors, it may interfere with peripartum opioid
efficacy requiring higher dosing. For intrapartum management, neuraxial anesthesia, spinal, and
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epidural methods are all appropriate for both labor pain and cesarean section. Fentanyl and
morphine can be used as neuraxial narcotics to provide pain relief. Local anesthetics may require
higher dosing to provide pain relief, however opioid tolerance may decrease the efficacy of local
anesthetics. Postpartum pain management will vary based on clinical and psychological context
of the mother’s pain. Both vaginal and cesarean delivery mothers should continue maintenance
of the opioid therapy, such as buprenorphine, postpartum. Additionally, postpartum pain
medication will be needed to a greater extent than non-opioid mothers, due to opioid-tolerance.
Postpartum medication options include NAIDs (ketorolac or ibuprofen). Mothers receiving
neuraxial anesthesia for labor or anesthesia may benefit from neuraxial morphine to aid in
reduction of postpartum breakthrough pain. Epidural catheters and peripheral nerve blocks are
also beneficial for these patients. This article serves as a good foundation for knowledge and
understanding of the challenges and complications that arise when caring for individuals
receiving MAT.

Figure 1 – Pan et al., discusses effective peripartum pain treatment options
compatible with opioid antagonists in mothers for both cesarean section and
vaginal delivery (2017).
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Meyer et al., in 2010, conducted a study with the objective of determining whether
buprenorphine maintenance in opioid dependent mothers effect intrapartum and postpartum pain
or medication requirements. Sixty-three women taking buprenorphine, 44 with vaginal delivery
and 19 with cesarean delivery, were matched to control women. Analgesic medication and pain
scores were assessed. Results yield no differences in intrapartum pain or analgesia needs in
buprenorphine mothers compared to control mothers. Buprenorphine mothers who underwent
vaginal delivery reported increased pain postpartum but required no increase in opioid pain
management. However, the buprenorphine mothers who underwent cesarean delivery had greater
analgesia needs and experienced greater postpartum pain. This study helps providers understand
that despite taking opioid agonist and/or antagonist, these individuals are still experiencing
equivocal pain to those not receiving MAT for opioid dependence, and their pain is legitimate
and requires management. There is additional complexity in managing these patients’ pain, due
to their increased analgesia needs. This information is beneficial for providers to help understand
the needs of these patient and how to provide adequate care.
Discussion
In opioid dependent pregnant women how does use of buprenorphine-naloxone compare
to buprenorphine monotherapy in maternal and neonatal safety?
Regarding adverse effects, the study done by Juma et al. in 2016 maternal and neonatal
outcomes were compared in mothers taking buprenorphine-naloxone, mothers taking opioids,
and mothers taking no opioids. Results showed no differences between Apgar scores and
caesarean rates between buprenorphine-naloxone exposure and no opioid exposure. This
suggests use of buprenorphine-naloxone use during pregnancy poses low risk to mother and
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baby. Furthermore, Juma et al. found mothers using buprenorphine-naloxone had higher, healthy
birth-weight babies compared to mothers taking other opioids, suggesting improved neonatal
outcomes with MAT versus without.
Regarding maternal and neonatal adherence and risk of withdrawal, Tran et al further
elaborates on inclusion of naloxone component. If the patient were to abuse the buprenorphinenaloxone product, there is potential for naloxone exposure to the neonate which then precipitate
maternal and/or neonate withdrawal. For this reason, Tran et al. finds buprenorphine monoproduct more favorable. On the contrary, Zoorob et al. finds buprenorphine-naloxone
combination product preferred due to its lower risk of misuse by inclusion of naloxone.
In summary, buprenorphine has been well studied, and shows improved maternal and
neonatal outcomes compared to opioid use. However, both monotherapy and combination
therapy have risk for abuse and misuse, therefore providers should be well educated on both
potential adverse effects and decide based each unique patient. Lastly, as discussed by Poon et al,
whichever medication is decided upon, it should be continued throughout pregnancy, and should
not be discontinued or transitioned.
In opioid dependent pregnant women how does use of buprenorphine-naloxone compare
to buprenorphine monotherapy in reduction of NAS?
When comparing combination therapy and monotherapy in reduction of NAS, very few
studies have identified significant difference. Mullins et al. 2019 found that combination therapy
did have a lower rate of NAS when compared to monotherapy. With this information providers
can reassure mothers that between monotherapy and combination therapy, no significant
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difference has been found in reduction of NAS. The decision should be ultimately make to best
suit the mother, as evaluated and decided by the trained provider.
In opioid dependent pregnant women how does use of buprenorphine-naloxone compared
to buprenorphine monotherapy effect management of peripartum pain?
Few specific studies were found that evaluated the role of naloxone in MAT and assess
postpartum pain management. However, if the medication is use appropriately there is poor oral
absorption of naloxone making it essential non-existent systemically. Therefore, combination
therapy including naloxone should not interact with systemic or neuraxial pain medications. The
primary takeaway from the research done on MAT mothers and managing peripartum pain, is
that these patients’ pain is more difficult to manage. Both providers and anesthesia should be
aware of this unique population and educated on how to best provide them with pain
management.
Clinical Application
As the number of providers become MAT certified increase, the information provided in
the literature review will assist the medical provider in making the safest and most efficacious
decision for management of opioid dependence in pregnant women or women of childbearing
age. With more providers becoming trained in prescribing MAT, it will be important to
understand what form best fits the patient based on their lifestyle and needs. MAT during
pregnancy has several layers of complexity, as it is researching a low compliance population, but
also researching medication use during pregnancy which many mothers are opposed to.
However, the evidence is sufficient in comparing MAT to opioid use in pregnancy for both
maternal and neonatal outcomes.
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